Q32 Bio Inc.
QTTBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Q32 Bio Inc. (QTTB) is listed under Biotechnology. Valued at $190.1M, QTTB is a micro-cap name in its sector. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Market Cap
$190.1M
Beta
-0.27
P/E (TTM)
4.52
P/E (Fwd)
-2.09
EPS (TTM)
$2.48
EPS (Fwd)
$-5.36
ROE
157.2%
ROA
18.8%
Cash
$50.8M
Total Debt
$13.6M
Free CF
$9.9M
52W Change
373.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $50.8M in cash comfortably exceeding the $13.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $9.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 157.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 18.8% further supports the picture of efficient asset utilization. Revenue has grown from $6.7M (2022) to $53.7M (2025), reflecting a 708% increase over the period.
The relatively low beta of -0.27 suggests QTTB is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Q32 Bio Inc.'s trajectory.